Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

Millions of bottles of over-the-counter cooling eye drops have been recalled across the United States after the US Food and Drug Administration (FDA) raised concerns that the products may not be sterile. Sterility issues raises the risk of eye infections significantly.

The FDA has classified the recall as a Class II recall. An FDA Class II recall for a product refers to the public health action that may cause temporary health problems, where the chance of serious harm is remote.

This recall covers nearly 12 million bottles of eight Rohto cooling eye drop products. The agency said the recall was initiated on July 14, due to a “lack of assurance of sterility” in the affected products.

The eye drops were manufactured in Vietnam and distributed nationwide by The Mentholatum Company.

Which Products Are Affected In The Recall?

The recent FDA recall includes several popular Rohto products, including:

1. Rohto All-in-One
2. Rohto Max Strength
3. Rohto Cool Relief
4. Rohto Dry Aid
5. Rohto Digi Eye
6. Rohto Optic Glow
7. Twin-pack versions of some of these products

The food and drugs regulatory body has warned consumers to stop using the recalled eye drops immediately and check the FDA’s recall notice for affected lot numbers and expiration dates.

Also read: FDA Recalls Popular Thyroid Medication: What Levothyroxine Users Need to Know

Is Sterility A Serious Concern?

Unlike tablets or capsules, eye drops are applied directly onto the eye. The process has limited natural protection against harmful microorganisms.

When sterility cannot always be guaranteed, bacteria or fungi may contaminate the solution easily.

Using contaminated eye drops significantly increases the risk of eye irritation, painful infections, damage to the corneas and, in extreme cases, vision loss.

Although the FDA has not disclosed any confirmed adverse effects linked to this recall, it said the products were withdrawn from the market as a precaution because ophthalmic products must strictly remain sterile throughout their shelf life.

The agency classified the recall as Class II, meaning exposure could cause temporary or reversible health effects, while serious harm is mostly unlikely.

Also read: US FDA Approves New Blood Test To Screen For Colorectal Cancer

Commenting on previous FDA recalls, Dr Gary Novack, clinical professor in the Department of Ophthalmology and Vision Science at UC Davis, said, “For eye drops, that means strict sterility, ensuring products are free from microorganisms like bacteria.”

He also said that manufacturing facilities must maintain contamination-free conditions because medicines used in the eye bypass many of the body’s natural defence mechanisms.

Dr Jeffrey H. Ma, ophthalmologist at the UC Davis Eye Center, also advised patients not to use recalled products: “Drops that are not on the recall list should be safe to use. If you have any of the drops on the list, you should immediately throw them away.”

What Should You Do If You Have The Recalled Products?

Health authorities recommend that people:

• Stop using any recalled Rohto eye drops immediately.
• Check product lot numbers and expiry dates against the FDA recall list.
• Contact a healthcare provider if they experience eye pain, redness, blurred vision, discharge or persistent irritation after using the recalled products.
• Return or safely dispose of affected products according to the manufacturer’s instructions.

The latest recall comes after multiple eye drop recalls in recent years linked to manufacturing and sterility issues, highlighting growing scrutiny of ophthalmic products.

US President is reportedly asking Secretary of the US Department of Health and Human Services Robert F. Kennedy Jr to make more efforts to cut childhood vaccines in America, according to a media report.

The 80-year-old US president hopes to make “alleviating autism” a component of his legacy, and told Kennedy that he wasn’t making enough cuts to the US vaccination schedule, the Wall Street Journal reported. The report, citing sources, said that Trump believes cutting down the number of recommended childhood vaccines may lead to a drop in autism rates in the country.

He, thus, expressed frustration with the slow pace of progress on the issue at a mid-June Oval Office meeting with Kennedy.

“Donald Trump has been anti-vaccine at least since 2015,” said Paul Offit, director of the Vaccine Education Center and an infectious diseases physician at Children’s Hospital of Philadelphia. At the Republican primary debate that year, Trump said that autism had gotten “totally out of control” and vaccines should be in “smaller doses over a longer period of time”.

Further, Trump reportedly also wants to break the combination vaccine for the measles, mumps, and rubella vaccination (MMR) into different shots, to reduce the risk of autism.

However, there has been no scientific evidence to prove that paring down the childhood vaccine schedule can reduce autism rates. Similarly, studies over the years have shown no connection between the MMR and autism.

Kennedy, last year, cancelled roughly $500 million in mRNA vaccine research grants and removed every single member of an immunization advisory panel.

But after White House aides told Kennedy that vaccine skepticism was less popular with voters, and they asked him to focus on more palatable topics, such as food reform, the Health Secretary has largely been mum on vaccines publicly. Trump’s recent urgency on the issue ignores his political advisers’ warnings.

CDC Makes Changes To Its Autism And Vaccine Webpage

Meanwhile, the US Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines is reigniting the debate over how health agencies should communicate scientific evidence.

The controversy was sparked by changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.

The page also says the HHS is continuing to investigate the causes of autism.

The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.

Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.

The changes have also drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.

Scientific Consensus Remains Intact

Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed. Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.

Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.

Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.

The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.

For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.

A new study suggests that nearly one in three adults in the United States could benefit from blood pressure-lowering medication under the latest treatment guidelines.

Yet millions who qualify are either not taking medication or have blood pressure that remains above recommended targets, highlighting a major gap in hypertension care.

The findings, published in JAMA, analysed data from the U.S. National Health and Nutrition Examination Survey (NHANES) collected between 2021 and 2023.

Researchers evaluated how the updated 2025 American Heart Association (AHA) and American College of Cardiology (ACC) blood pressure guidelines would affect treatment eligibility.

Unchecked Hypertension Crisis

According to the researchers, an estimated 34 million U.S. adults, roughly one in three, meet the criteria for blood pressure medication but are not currently taking it.

Nearly 19 million of them have blood pressure readings of 140/90 mmHg or higher, placing them at increased risk of heart attack, stroke, kidney disease, and dementia if left untreated.

The study also found that almost 80% of adults with hypertension have blood pressure levels above the recommended treatment goal of less than 130/80 mmHg.

Also read: Not Just The Heart, Obesity In Midlife Could Be Just As Harmful To The Brain: Study

Treatment Gap

Researchers observed that many adults with high blood pressure were not taking any antihypertensive medication, despite being eligible under current guidelines.

Among those who were not receiving treatment, about two-thirds had blood pressure values within 10 mmHg of the recommended target.

The observation suggested that a combination of medication and lifestyle changes could help many get their readings down.

On the other hand, people who were already taking medication often had blood pressure levels that remained well above target, indicating that medication may need to be intensified.

The authors wrote, “Many could potentially achieve blood pressure control with initiation of antihypertensive medication and lifestyle modification.”

They further noted, “These findings highlight a large gap in hypertension control that implementation of the 2025 AHA/ACC blood pressure guideline recommendations could address.”

Also read: Smoking, Diabetes, High Blood Pressure May Fuel the Most Dangerous Type of Artery Plaque, Study Finds

High BP Is The Silent Killer

High blood pressure is often called the “silent killer” because it usually causes no symptoms while quietly damaging blood vessels and vital organs over time.

According to the U.S. Centers for Disease Control and Prevention (CDC), uncontrolled hypertension is a major contributor to heart disease and stroke, two of the leading causes of death in the country.

Researchers also pointed out that more than 80% of adults with uncontrolled blood pressure had health insurance and a regular place for medical care, suggesting that access alone does not fully explain why treatment goals are not being met.

Also read: Why Lifestyle Diseases Don't Take A Break During The Monsoon—Managing Diabetes, Hypertension, And Heart Conditions

Recommended Lifestyle Changes

The updated AHA/ACC guidelines emphasise that treatment should not rely on medication alone. Doctors recommend:

• Following a heart-healthy diet
• Reducing salt intake
• Maintaining a healthy weight
• Exercising regularly
• Avoiding alcohol
• Quitting smoking
• Taking prescribed medicines consistently
• Attending regular follow-up appointments

As hypertension continues to affect millions, researchers say earlier diagnosis, timely treatment, and sustained lifestyle changes could substantially reduce the burden of cardiovascular disease and improve long-term health outcomes.